Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Daniel Peter Petrylak, Scott T. Tagawa, Rohit K. Jain, Manojkumar Bupathi, Arjun Vasant Balar, Arash Rezazadeh, Saby George, Phillip Lee Palmbos, Luke T. Nordquist, Nancy B. Davis, Nicholas J. Vogelzang, Chethan Ramamurthy, Cora N. Sternberg, Yohann Loriot, Neeraj Agarwal, Quan Hong, Allison Gladden, Charu Kanwal, Trishna Goswami, Petros Grivas
Institutions: Yale University, Weill Cornell Medicine, Moffitt Cancer Center, Rocky Mountain Cancer Centers, NYU Langone Health, New York University, Norton Healthcare, Roswell Park Comprehensive Cancer Center, U-M Rogel Cancer Center, Urology Cancer Center and GU Research Network, Vanderbilt-Ingram Cancer Center, Comprehensive Cancer Centers of Nevada, The University of Texas at San Antonio Health Science Center, Institut Gustave Roussy, University of Utah, Huntsman Cancer Institute, Immunomedics (United States), University of Washington
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3032085639